Penumbra Company Profile (NYSE:PEN)

About Penumbra

Penumbra logoPenumbra, Inc. (Penumbra) is an interventional therapies company. The Company designs, develops, manufactures and markets medical devices. The Company has a portfolio of products that addresses medical conditions and significant clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. The Company focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Ischemic Stroke, Neurovascular Embolization and Neurosurgical Tools. The Company's peripheral vascular products include Peripheral Embolization and Peripheral Thrombectomy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: PEN
  • CUSIP:
Key Metrics:
  • Previous Close: $78.85
  • 50 Day Moving Average: $73.20
  • 200 Day Moving Average: $70.16
  • 52-Week Range: $41.35 - $79.90
  • Trailing P/E Ratio: 3178.00
  • Foreward P/E Ratio: -1,958.75
  • P/E Growth: -16.98
  • Market Cap: $2.51B
  • Outstanding Shares: 31,643,000
  • Beta: 0.15
Profitability:
  • Net Margins: 0.61%
  • Return on Equity: 0.61%
  • Return on Assets: 0.53%
Debt:
  • Current Ratio: 7.16%
  • Quick Ratio: 5.28%
Additional Links:
Companies Related to Penumbra:

Analyst Ratings

Consensus Ratings for Penumbra (NYSE:PEN) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $76.50 (2.36% downside)

Analysts' Ratings History for Penumbra (NYSE:PEN)
Show:
DateFirmActionRatingPrice TargetDetails
10/17/2016BMO Capital MarketsInitiated CoverageOutperform$86.00View Rating Details
7/20/2016Canaccord GenuitySet Price TargetBuy$67.00View Rating Details
3/14/2016Wells Fargo & CompanyReiterated RatingOutperformView Rating Details
10/13/2015Bank of America CorpInitiated CoverageBuy -> Buy$46.00 -> $46.00View Rating Details
10/13/2015J P Morgan Chase & CoInitiated CoverageOverweight$46.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Penumbra (NYSE:PEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017Q416($0.09)$67.54 millionN/AView Earnings Details
11/3/2016Q316($0.08)($0.04)$63.25 million$67.20 millionViewN/AView Earnings Details
8/9/2016Q216($0.07)$0.01$58.18 million$65.10 millionViewN/AView Earnings Details
5/9/2016Q116($0.07)$0.02$53.10 million$57.90 millionViewN/AView Earnings Details
3/8/2016Q415($0.10)$0.05$46.76 million$54.40 millionViewN/AView Earnings Details
11/12/2015Q315($0.15)$0.03$43.00 million$50.42 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Penumbra (NYSE:PEN)
Current Year EPS Consensus Estimate: $-0.10 EPS
Next Year EPS Consensus Estimate: $-0.04 EPS

Dividends

Dividend History for Penumbra (NYSE:PEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Penumbra (NYSE:PEN)
Insider Ownership Percentage: 22.00%
Institutional Ownership Percentage: 57.64%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/14/2017Robert D EvansEVPSell5,000$75.00$375,000.00View SEC Filing  
2/13/2017Adam ElsesserCEOSell7,700$72.21$556,017.00View SEC Filing  
2/13/2017James Robert PrayInsiderSell1,700$73.04$124,168.00View SEC Filing  
2/13/2017Sridhar KosarajuCFOSell1,600$72.94$116,704.00View SEC Filing  
2/10/2017James Robert PrayInsiderSell23,900$71.08$1,698,812.00View SEC Filing  
2/10/2017Sridhar KosarajuCFOSell15,500$71.49$1,108,095.00View SEC Filing  
2/9/2017Arani BoseInsiderSell22,300$70.44$1,570,812.00View SEC Filing  
2/9/2017Lynn RothmanEVPSell2,700$70.20$189,540.00View SEC Filing  
2/7/2017James Robert PrayInsiderSell4,099$69.09$283,199.91View SEC Filing  
2/7/2017Robert D EvansEVPSell1$70.00$70.00View SEC Filing  
2/6/2017Arani BoseInsiderSell17,100$70.01$1,197,171.00View SEC Filing  
2/6/2017Lynn RothmanEVPSell2,886$70.41$203,203.26View SEC Filing  
2/6/2017Sridhar KosarajuCFOSell100$70.00$7,000.00View SEC Filing  
2/3/2017James Robert PrayInsiderSell15,600$70.39$1,098,084.00View SEC Filing  
2/3/2017Robert D EvansEVPSell5,000$70.35$351,750.00View SEC Filing  
2/3/2017Sridhar KosarajuCFOSell7,800$70.56$550,368.00View SEC Filing  
2/1/2017Adam ElsesserCEOSell21,400$70.98$1,518,972.00View SEC Filing  
2/1/2017Daniel Donen DavisInsiderSell7,298$71.00$518,158.00View SEC Filing  
2/1/2017Lynn RothmanEVPSell4,414$70.99$313,349.86View SEC Filing  
1/31/2017Adam ElsesserCEOSell9,000$71.26$641,340.00View SEC Filing  
1/31/2017Daniel Donen DavisInsiderSell3,000$71.29$213,870.00View SEC Filing  
1/31/2017Lynn RothmanEVPSell1,800$71.27$128,286.00View SEC Filing  
1/30/2017Adam ElsesserCEOSell8,200$70.72$579,904.00View SEC Filing  
1/30/2017Daniel Donen DavisInsiderSell2,698$70.71$190,775.58View SEC Filing  
1/30/2017Lynn RothmanEVPSell1,700$70.79$120,343.00View SEC Filing  
1/27/2017Arani BoseInsiderSell31,500$74.12$2,334,780.00View SEC Filing  
1/27/2017Lynn RothmanEVPSell7,000$74.24$519,680.00View SEC Filing  
1/26/2017Don W KassingDirectorSell3,000$74.50$223,500.00View SEC Filing  
11/16/2016Sridhar KosarajuCFOSell25,000$65.07$1,626,750.00View SEC Filing  
9/9/2016Adam ElsesserCEOSell57,200$71.07$4,065,204.00View SEC Filing  
9/6/2016Arani BoseInsiderSell61,000$70.72$4,313,920.00View SEC Filing  
9/2/2016Robert D EvansEVPSell3,100$70.10$217,310.00View SEC Filing  
8/31/2016Adam ElsesserCEOSell26,000$71.15$1,849,900.00View SEC Filing  
8/31/2016Robert D EvansEVPSell5,300$71.17$377,201.00View SEC Filing  
8/26/2016Adam ElsesserCEOSell26,800$71.06$1,904,408.00View SEC Filing  
8/26/2016Robert D EvansEVPSell5,300$71.03$376,459.00View SEC Filing  
8/24/2016Adam ElsesserCEOSell29,000$72.95$2,115,550.00View SEC Filing  
8/24/2016Robert D EvansEVPSell6,300$73.00$459,900.00View SEC Filing  
5/23/2016Robert D EvansEVPSell5,000$50.52$252,600.00View SEC Filing  
5/19/2016Don W KassingDirectorSell3,000$48.63$145,890.00View SEC Filing  
5/19/2016Robert D EvansEVPBuy1,538$25.50$39,219.00View SEC Filing  
5/16/2016James Robert PrayInsiderSell32,500$48.51$1,576,575.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Penumbra (NYSE:PEN)
DateHeadline
News IconUse of Aspiration as Frontline Thrombectomy Therapy for Acute Ischemic Stroke (NYSE:PEN)
www.medindia.net - February 24 at 8:34 AM
News IconStudy supports use of aspiration as frontline thrombectomy therapy for acute ischemic stroke (NYSE:PEN)
scienmag.com - February 23 at 12:19 AM
News IconASTER Evaluates Penumbra’s Aspiration System in Acute Ischemic Stroke (NYSE:PEN)
evtoday.com - February 23 at 12:19 AM
News IconStock Circle: Looking Closer at Shares of Penumbra, Inc. (NYSE:PEN) - Searcy News (NYSE:PEN)
searcysentinel.com - February 22 at 7:19 PM
businesswire.com logoIndependent Study Supports Use of Penumbra Aspiration as Frontline Thrombectomy Therapy for Acute Ischemic Stroke - Business Wire (press release) (NYSE:PEN)
www.businesswire.com - February 22 at 7:19 PM
finance.yahoo.com logoIndependent Study Supports Use of Penumbra Aspiration as Frontline Thrombectomy Therapy for Acute Ischemic Stroke (NYSE:PEN)
finance.yahoo.com - February 22 at 7:19 PM
finance.yahoo.com logoCan Penumbra (PEN) Spring a Surprise this Earnings Season? (NYSE:PEN)
finance.yahoo.com - February 22 at 9:16 AM
News IconMomentum Watch on Shares of Penumbra, Inc. (NYSE:PEN) - Sherwood Daily (NYSE:PEN)
sherwooddaily.com - February 21 at 5:41 PM
News IconEndovascular Therapy in Stroke: Who Should Do What? (NYSE:PEN)
www.medscape.com - February 16 at 6:45 PM
News IconIs The Sell-Side Predicting That Penumbra Inc (NYSE:PEN) Will Move Higher? - Winfield Review (NYSE:PEN)
winfieldreview.com - February 16 at 6:45 PM
prnewswire.com logoPenumbra, Inc. Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call for February 28 ... - PR Newswire (press release) (NYSE:PEN)
www.prnewswire.com - February 16 at 6:45 PM
finance.yahoo.com logoQuest Diagnostics (DGX) Launches HBV Quantitative Test (NYSE:PEN)
finance.yahoo.com - February 14 at 11:17 PM
finance.yahoo.com logoPenumbra, Inc. Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call for February 28, 2017 at 5:00 PM Eastern Time (NYSE:PEN)
finance.yahoo.com - February 14 at 11:17 PM
openpr.com logoInterventional Neurology Market- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024 (NYSE:PEN)
www.openpr.com - February 14 at 3:16 AM
News IconProcess Improvement in Stroke Care (NYSE:PEN)
evtoday.com - February 13 at 10:00 PM
streetinsider.com logoForm 4 Penumbra Inc For: Feb 07 Filed by: Davis Daniel Donen - StreetInsider.com (NYSE:PEN)
www.streetinsider.com - February 11 at 7:14 PM
News IconNew report examines the Global neurovascular devices market that is poised to grow at a CAGR of 8.1% (NYSE:PEN)
www.whatech.com - February 10 at 8:09 PM
streetinsider.com logoForm 4 Penumbra Inc For: Feb 08 Filed by: Pray James Robert (NYSE:PEN)
www.streetinsider.com - February 10 at 8:09 PM
streetinsider.com logoForm 4 Penumbra Inc For: Feb 07 Filed by: Davis Daniel Donen (NYSE:PEN)
www.streetinsider.com - February 10 at 2:01 AM
News IconTechnical Focus on Shares of Penumbra Inc (PEN) - Benton Bulletin (NYSE:PEN)
bentonbulletin.com - February 9 at 9:00 PM
streetinsider.com logoForm 4 Penumbra Inc For: Feb 06 Filed by: Evans Robert D. (NYSE:PEN)
www.streetinsider.com - February 9 at 1:10 AM
sbwire.com logoAcute Ischemic Stroke Diagnosis and Treatment Market, by Geography and Forecast Up to 2020 (NYSE:PEN)
www.sbwire.com - February 8 at 8:10 PM
streetinsider.com logoForm 4 Penumbra Inc For: Feb 02 Filed by: Bose Arani (NYSE:PEN)
www.streetinsider.com - February 8 at 1:30 AM
streetinsider.com logoForm 4 Penumbra Inc For: Feb 02 Filed by: Bose Arani - StreetInsider.com (NYSE:PEN)
www.streetinsider.com - February 7 at 8:27 PM
News IconNeurointerventional Devices Market to expand at a CAGR of 4.8% through 2015 to 2025 (NYSE:PEN)
reports.pr-inside.com - February 6 at 9:09 AM
streetinsider.com logoForm 4 Penumbra Inc For: Feb 01 Filed by: Pray James Robert (NYSE:PEN)
www.streetinsider.com - February 4 at 1:02 AM
streetinsider.com logoForm 4 Penumbra Inc For: Jan 30 Filed by: Rothman Lynn - StreetInsider.com (NYSE:PEN)
www.streetinsider.com - February 3 at 1:09 AM
streetinsider.com logoForm 4 Penumbra Inc For: Jan 30 Filed by: Rothman Lynn (NYSE:PEN)
www.streetinsider.com - February 2 at 2:06 AM
News IconMarket Research on Peripheral Embolization Device Market 2016 and Analysis to 2026 (NYSE:PEN)
reports.pr-inside.com - February 1 at 9:03 PM
News IconReviewing Individual Broker Targets Of Penumbra, Inc. (NYSE:PEN ... - NewsDen (NYSE:PEN)
newsden.net - January 31 at 5:51 AM
News IconGlobal Neurovascular Devices Market Size, Share, Analysis Industry Growth and Forecast 2022 (NYSE:PEN)
www.medgadget.com - January 30 at 7:51 PM
News IconInvestor Hub: Checking on the Numbers for Penumbra, Inc. (NYSE:PEN) - The Tribune (NYSE:PEN)
lakecitytribune.com - January 30 at 8:35 AM
News IconSell-side is Weighing in on Penumbra Inc (NYSE:PEN) Earnings & Targets - Aiken Advocate (NYSE:PEN)
aikenadvocate.com - January 30 at 8:35 AM
News IconWatching the ATR on Shares of Penumbra Inc (PEN) - Market Point (NYSE:PEN)
mtptnews.com - January 30 at 8:35 AM
News IconStock Tracker: Looking at the Numbers for Penumbra, Inc. (NYSE:PEN) - The Tribune (NYSE:PEN)
lakecitytribune.com - January 28 at 5:37 AM
sbwire.com logoBlood Clot Retrieval Devices Market Trends 2016-2026 (NYSE:PEN)
www.sbwire.com - January 28 at 5:37 AM
streetinsider.com logoForm 4 Penumbra Inc For: Jan 25 Filed by: Rothman Lynn - StreetInsider.com (NYSE:PEN)
www.streetinsider.com - January 28 at 5:37 AM
streetinsider.com logoForm 4 Penumbra Inc For: Jan 25 Filed by: Rothman Lynn (NYSE:PEN)
www.streetinsider.com - January 28 at 5:37 AM
News IconBlood Clot Retrieval Devices Market Segments and Key Trends 2016-2026 (NYSE:PEN)
reports.pr-inside.com - January 27 at 5:40 AM
openpr.com logoThrombectomy Devices Market Is Expected to Reach $1,389 Million, Globally, by 2022 (NYSE:PEN)
www.openpr.com - January 27 at 5:40 AM
News IconStock Tracker: Earnings & Estimates for Penumbra Inc (NYSE:PEN) - Aiken Advocate (NYSE:PEN)
aikenadvocate.com - January 27 at 12:39 AM
News IconRedmile Group LLC Boosted Its Position in Amicus Therapeutics INC (FOLD) as Share Price Rose (NYSE:PEN)
randolphguide.com - January 24 at 7:56 PM
News IconEarnings in Full Force, Analysts Take Aim at Penumbra Inc (NYSE:PEN) - Wall Street Beacon (NYSE:PEN)
wsbeacon.com - January 24 at 8:39 AM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: Penumbra, Inc. (NYSE:PEN) - Wall Street Beacon (NYSE:PEN)
wsbeacon.com - January 22 at 6:57 PM
News IconTrump Sworn In as S&P Declined, How Did this Stock Perform This Week: Penumbra, Inc. (NYSE:PEN) - Aiken Advocate (NYSE:PEN)
aikenadvocate.com - January 21 at 11:58 PM
News IconIs This Stock Fairly Valued Heading Into Earnings Season: Penumbra, Inc. (NYSE:PEN) - Aiken Advocate (NYSE:PEN)
aikenadvocate.com - January 20 at 5:03 AM
finance.yahoo.com logoCan The Uptrend Continue for Penumbra (PEN)? (NYSE:PEN)
finance.yahoo.com - January 20 at 12:00 AM
News IconWill The Needle Move For Penumbra Inc (NYSE:PEN) Shares This Earnings Season? - Wall Street Beacon (NYSE:PEN)
wsbeacon.com - January 19 at 12:45 AM
News IconRating Sentiment On Watch: Are Analysts Bullish about Penumbra Inc (NYSE:PEN) after last week? - Fair View Times (NYSE:PEN)
fairviewtimes.com - January 19 at 12:45 AM
openpr.com logoGlobal Peripheral Embolization Device Market Trends, Regulations And Competitive Landscape Outlook to 2026 (NYSE:PEN)
www.openpr.com - January 18 at 8:41 AM

Social

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Where is Penumbra's stock going? Where will Penumbra's stock price be in 2017?

3 brokers have issued 12-month price objectives for Penumbra's stock. Their predictions range from $67.00 to $86.00. On average, they anticipate Penumbra's share price to reach $76.50 in the next twelve months.

When will Penumbra announce their earnings?

Penumbra is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.

Who owns Penumbra stock?

Penumbra's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Federated Investors Inc. PA (1.64%), State Street Corp (1.49%), Champlain Investment Partners LLC (0.98%), Franklin Resources Inc. (0.64%) and Artisan Partners Limited Partnership (0.49%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Daniel Donen Davis, Don W Kassing, James Robert Pray, Lynn Rothman, Robert D Evans and Sridhar Kosaraju.

Who sold Penumbra stock? Who is selling Penumbra stock?

Penumbra's stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management AG, Highland Capital Management LP, AQR Capital Management LLC, Mission Wealth Management LLC, Nicholas Investment Partners LP and Franklin Resources Inc.. Company insiders that have sold Penumbra stock in the last year include Adam Elsesser, Arani Bose, Daniel Donen Davis, Don W Kassing, James Robert Pray, Lynn Rothman, Robert D Evans and Sridhar Kosaraju.

Who bought Penumbra stock? Who is buying Penumbra stock?

Penumbra's stock was acquired by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Federated Investors Inc. PA, Artisan Partners Limited Partnership, FMR LLC, Russell Investments Group Ltd., Loomis Sayles & Co. L P, State Street Corp and Advisory Research Inc..

How do I buy Penumbra stock?

Shares of Penumbra can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Penumbra stock cost?

One share of Penumbra stock can currently be purchased for approximately $78.35.

Penumbra (NYSE:PEN) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Penumbra (NYSE:PEN)

Earnings History Chart

Earnings by Quarter for Penumbra (NYSE:PEN)

Dividend History Chart

Dividend Payments by Quarter for Penumbra (NYSE:PEN)

Last Updated on 2/24/2017 by MarketBeat.com Staff